Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

78.36 USD -1.24 (-1.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 23, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 578,335
Open 79.61
Bid (Size) 78.01 (1)
Ask (Size) 80.00 (1)
Prev. Close 79.60
Today's Range 78.03 - 80.00
52wk Range 67.68 - 181.83
Shares Outstanding 79,774,575
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Sarepta Therapeutics to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases

Performance

YTD
-52.59%
-52.59%
1 Month
+1.49%
+1.49%
3 Month
+4.51%
+4.51%
6 Month
-55.99%
-55.99%
1 Year
-53.58%
-53.58%

More News

Read More
4 Biotech Stocks To Watch This Week
Tags Market News
From StockMarket.com
Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta’s Commercial P
From GlobeNewswire News Releases
Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
From GlobeNewswire News Releases
How The Parts Add Up: FBT Targets $202
Tags ETFs
From ETF Channel
Why Did the FDA Approve Biogen's Alzheimer's Disease Drug After an Advisory Panel Recommended Against It?
Tags Market News BIIB SRPT
From Motley Fool
Noteworthy Tuesday Option Activity: SRPT, LULU, AXON
Tags Stocks
From Market News Video
Sarepta's Stock Trading Higher As Duchenne Muscular Dystrophy Gene Therapy Shows Promise In Open-Label Study
Tags gene therapy Biotech Movers
From Benzinga
3 Popular Stocks Money Managers Couldn't Stop Selling in Q1
Tags GME SRPT TSLA
From Motley Fool
Why Sarepta Might Have Just Reversed Its Fortunes In Gene Therapy
From Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.